<code id='397FCA5693'></code><style id='397FCA5693'></style>
    • <acronym id='397FCA5693'></acronym>
      <center id='397FCA5693'><center id='397FCA5693'><tfoot id='397FCA5693'></tfoot></center><abbr id='397FCA5693'><dir id='397FCA5693'><tfoot id='397FCA5693'></tfoot><noframes id='397FCA5693'>

    • <optgroup id='397FCA5693'><strike id='397FCA5693'><sup id='397FCA5693'></sup></strike><code id='397FCA5693'></code></optgroup>
        1. <b id='397FCA5693'><label id='397FCA5693'><select id='397FCA5693'><dt id='397FCA5693'><span id='397FCA5693'></span></dt></select></label></b><u id='397FCA5693'></u>
          <i id='397FCA5693'><strike id='397FCA5693'><tt id='397FCA5693'><pre id='397FCA5693'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:explore    Page View:33
          Ron Wyden (left), Mike Crapo (right) -- health policy coverage from STAT
          Draft legislation authored by Senate Finance Chair Ron Wyden (D-Ore.) and ranking member Mike Crapo (R-Idaho) includes several measures to regulate how pharmacy benefit managers are paid by health plans to negotiate with drugmakers. Pete Marovich-Pool/Getty Images

          WASHINGTON — A key Senate health care panel has developed a plan to tackle reforms to middlemen in the pharmacy drug payment system, according to bill text obtained by STAT.

          The draft legislation, authored by Senate Finance Chair Ron Wyden (D-Ore.) and ranking member Mike Crapo (R-Idaho), includes several measures to regulate how pharmacy benefit managers are paid by health plans to negotiate with drugmakers.

          advertisement

          The most significant measure is a bill from Sens. Bob Menendez (D-N.J.) and Marsha Blackburn (R-Tenn.) that would prohibit PBMs from getting any income outside of service fees, and prohibits those service fees from being related to drugs’ list prices.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Wikipedia

          Psychedelics group wrestles with new pharma identity
          Psychedelics group wrestles with new pharma identity

          OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

          read more
          Disappointing trial forces Pfizer to pivot on obesity medicine plans
          Disappointing trial forces Pfizer to pivot on obesity medicine plans

          MarkLennihan/APPfizeronFridaysaiditwasstoppingdevelopmentofatwice-dailyoralobesitymedicationafteranu

          read more
          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more

          Chemotherapy before breast cancer surgery might fuel metastasis

          Abreastcancertumorimagedwithatechniquethathighlightsaspectsofitsmicroenvironment.NationalCancerInsti